U.S. markets open in 2 hours 40 minutes

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
27.76+0.64 (+2.36%)
At close: 04:00PM EDT
29.14 +1.38 (+4.97%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close27.12
Bid11.08 x 1100
Ask0.00 x 800
Day's Range26.55 - 27.82
52 Week Range19.35 - 43.61
Avg. Volume382,348
Market Cap1.653B
Beta (5Y Monthly)0.80
PE Ratio (TTM)15.60
EPS (TTM)1.78
Earnings DateAug 02, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
53% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for XNCR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xencor, Inc.
    XNCR: Raising target price to $26.00XENCOR INC has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Business Wire

    Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

    MONROVIA, Calif., May 26, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®104, a PD-1 x ICOS bispecific antibody, in patients with advanced solid tumors (DUET-3). These results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), during the poster

  • InvestorPlace

    7 High-Risk, High-Reward Small-Cap Stocks to Buy Now

    On a valuation basis, these small-cap stocks could be stocks to buy for long-term gains. Monro (MNRO): A good-quality stock you can buy now or wait for lower prices in. Jack in the Box (JACK): A well-known franchise with a low-priced valuation. Ultra Clean Holdings (UCTT): Its low valuation and growing earnings make it a stock to buy. Patrick Industries (PATK): It remains a stock to buy, even in this market environment. Xencor (XNCR): It had weak earnings, but watch this stock for a buying point

  • Simply Wall St.

    Declining Stock and Decent Financials: Is The Market Wrong About Xencor, Inc. (NASDAQ:XNCR)?

    Xencor (NASDAQ:XNCR) has had a rough three months with its share price down 20%. But if you pay close attention, you...